Myriad Genetics’ (MYGN) wholly-owned subsidiary Crescendo Bioscience said Thursday new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra DA test to predict joint damage were presented at the 2017 European League Against Rheumatism meeting in Madrid, Spain.
The key finding is that high Vectra DA score is associated with significantly increased risk of joint damage progression in a variety of patients with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, tumor necrosis factor-alpha inhibitors and abatacept.
“Importantly, this analysis confirms the consistency and robustness of the previous findings. This new information advances the understanding of the role of molecule biomarkers in RA and can help to facilitate the discussion on the role of biomarkers in RA treatment guidance,” said Crescendo Bioscience chief medical officer Elena Hitraya.
Data from more than 800 patients shows that a high Vectra DA score is associated with an increased risk of joint damage and is more predictive than conventional measures of RA, the company said in a press release.